ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-expressing Cancers
Conditions
HER2-expressing Cancers
Trial Timeline
Sep 30, 2016 → Oct 31, 2024
NCT ID
NCT02892123About ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib
ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib is a phase 1 stage product being developed by Jazz Pharmaceuticals for HER2-expressing Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT02892123. Target conditions include HER2-expressing Cancers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02892123 | Phase 1 | Completed |
Competing Products
6 competing products in HER2-expressing Cancers
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-4602 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-A1811 combined with Pyrotinib. + SHR-A1811 combined with other antitumor therapies | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| VIR-5818 + pembrolizumab | Merck | Phase 1/2 | 41 |
| ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine | Jazz Pharmaceuticals | Phase 2 | 49 |
| Zanidatamab + Evorpacept | Jazz Pharmaceuticals | Phase 1/2 | 38 |
| ZW49 | Zymeworks | Phase 1 | 28 |